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Abstract
Background: Despite advances in medical therapy, cardiovascular disease, mainly coronary artery disease (CAD),
remains the leading cause of mortality among patients with diabetes mellitus (DM). The objective of the present
study was to assess the effectiveness of dipyridamole stress echocardiography in identify diabetic patients at high
risk for cardiovascular events.
Methods: Dipyridamole stress echocardiography was administered to 483 diabetic patients (294 women; mean age
63.41 ± 11.28 years) between July 2006 and December 2012.
Results: Follow-up data were available for 264 patients (163 women; mean age 64.3 ± 10.5 years): 250 with a
negative stress echocardiography and 14 with a positive stress echo. During a mean follow-up time of 18 ±
14 months, a cardiovascular event occurred in 18 (6.8 %) patients, 12 (4.8 %) in patients with a negative stress echo
(n = 250) during a mean follow-up period of 20 ± 16 months and 6 (42 %) in patients with positive stress echo
(n = 14) during a mean follow-up of 13 ± 13 months. The positive and negative predictive values of stress
echocardiography were 42 % and 96 % respectively. The accuracy value was 92 %. A Cox regression model showed
that CAD (hazard ratio [HR] 5.4, 95 % confidence interval [CI] 1.9-15.4; p = 0.002) and positive stress
echocardiography (HR 7.1, 95 % CI 2.5-20.5; p < 0.001) were significant predictors of cardiovascular events.
Conclusions: For patients with diabetes, a negative dipyridamole stress echocardiogram predicts favorable
outcome during the first year of follow-up. A new stress imaging test should be done after 12 months in diabetic
patients.
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Background
Despite advances in medical therapy, cardiovascular dis-
ease, mainly coronary artery disease (CAD), remains the
leading cause of mortality among patients with diabetes
mellitus (DM). Indeed, DM has been classified as a coron-
ary heart disease equivalent by both the American Heart
Association and American College of Cardiology [1, 2]. In
addition, diabetes is associated with a higher rate of pro-
gression of coronary lesions, coronary occlusion, plaque
ulceration, thrombosis, and formation of new luminal nar-
rowing, which suggests that the features of vascular dis-
ease are different in diabetic and nondiabetic patients [3].
The challenge is to identify these high-risk patients early
in their disease using noninvasive imaging methods. In a
study assessing 1123 patients with type 2 diabetes and no
symptoms of CAD [4], the participants were randomly
assigned to be, or not to be, screened with adenosine-
stress radionuclide myocardial perfusion imaging (MPI).
The authors concluded that the cardiac event rates were
low and were not significantly reduced by MPI screening
for myocardial ischemia over 4.8 years. However, the
negative predictive value of stress echocardiography is
thought to be lower in patients with DM. Diabetic patients
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with a normal stress echocardiogram have a higher risk
for subsequent cardiovascular events than nondiabetic pa-
tients, especially in the second year after undergoing stress
echocardiography [5, 6]. Unlike a normal or negative
stress echocardiography, a positive echo stress test, or one
which detects ischemia, enables the identification of pa-
tients at greater risk of cardiac events [7, 8]. Moreover,
diabetic patients are more likely to have diffuse distal vas-
cular disease. In these patients regional wall motion ab-
normalities of the left ventricle are harder to identify by
stress echocardiography, because the reduced perfusion is
global instead of regional [8–13]. Now there are new
ultrasound imaging modalities that can identify early
changes in the myocardium [13, 14]; however these
modalities are not accessible to all patients and private
clinics and routine screening of millions of asymptom-
atic diabetic patients would be prohibitively expensive.
Most physicians use less expensive tests such as the
electrocardiographic (EKG) exercise test and pharma-
cological stress echocardiography to stratify their pa-
tients’ risk. Therefore, the purpose of this study was to
assess the effectiveness of dipyridamole stress echocar-




We retrospectively assessed 483 consecutive diabetic pa-
tients (294 women), with a mean age of 63.41 ± 11.28 years,
who underwent dipyridamole stress echocardiography be-
tween July 2006 and December 2012 in a private cardio-
logical clinic. Each patient’s blood sample results and
previous imaging exams were analyzed before the stress
echo test was performed. Before the study, the ultrasono-
graphist collected information on the patients’ demo-
graphic characteristics and risk factors, according to the
blood sample results and the report by the private cardiolo-
gist. Patients were questioned about the presence of hyper-
tension, DM, dyslipidemia, CAD, and current smoking
habit. Hypertension was defined as a history of treated
hypertension or the presence of systolic BP ≥ 140 mmHg
or diastolic BP ≥ 90 mmHg as measured by the private car-
diologist. Smoking history was coded as never or current
smoker. Subjects were classified as having diabetes when
treated for insulin-dependent or non-insulin-dependent
diabetes or having elevated fasting glucose levels
(≥126 mg/dL). Patients’ records included the use of lipid-
lowering drugs or the presence of total cholesterol >
200 mg/dL, HDL-cholesterol < 40 mg/dL, LDL - choles-
terol > 100 mg/dL or triglycerides > 150 mg/dL [15–17], as
well as a history of myocardial infarction, angioplasty, or
coronary artery bypass surgery was recorded. A positive
CAD history was considered to be the presence of any of
these previous conditions. No patient at the present study
presented a history of stroke or transient ischemic attack
or reported intermittent claudication suggesting peripheral
arterial disease. The reported indications for the exam in-
cluded referral from a physician, information from close
relatives, or the complaints of the participating patient.
The indication for a stress test and treatment were exclu-
sively offered by the private cardiologist. Twenty-seven
percent of the exams (n = 264) were performed for a rou-
tine clinical and imaging follow-up; i.e., diabetic patients
without other identifiable associated risk factor and with
no specific complaints. The second most frequent indica-
tion for testing was thoracic pain in 58 patients (22 %),
followed by perioperative risk stratification in 41 patients
(15 %), and assessment of known CAD (14 %). Other indi-
cations included changes in the resting EKG (7 %; atrial
fibrillation, left bundle branch block, right bundle branch
block, and ST segment abnormalities) and evaluation of
dyspnea/fatigue (4 %). Seventy patients underwent tread-
mill EKG stress testing using Bruce protocol before
pharmacologic stress echocardiography was performed.
Twenty-one patients had inconclusive exercise EKG test
results (they did not reach submaximal heart rate), and 49
patients had altered exercise EKG readings, suggestive of
coronary ischemic disease. The patients’ baseline charac-
teristics and the indications for pharmacological stress
echocardiography are shown in Tables 1 and 2. Moreover,
the tables include both the number of diabetic patients
who underwent dipyridamole stress echocardiography
(n = 483) and the actual number of patients from whom
we obtained data at the follow-up period (n = 264). Written
informed consent to undergo stress testing and to participate
in the study was obtained from each patient.
Follow-up data
Follow-up data were obtained after a minimum of
6 months from telephone interviews with the patient or
a close relative, or contact with the patient’s physician.
The cardiovascular events recorded during the follow-up
period were fatal and nonfatal myocardial infarction,
Table 1 Patients’ baseline characteristics
Patients (N) 483 264
Sex (M/F) 189/294 101/163
Age (y ± SD) 63.41 ± 11.28 64.3 ± 10.5
History of hypertension (N/%) 407 (84 %) 223 (84.5 %)
History of dyslipidemia (N/%) 329 (68 %) 181 (68.6 %)
Coronary artery disease (N/%) 68 (14 %) 37 (14 %)
Current smoking (N/%) 51 (10 %) 29 (11 %)
Altered/insufficient exercise stress testing
(N/%)
132 (27 %) 70 (26 %)
1Altered EKG (N/%) 30 (6 %) 19 (7 %)
1Altered EKG = atrial fibrillation, left bundle branch block, right bundle branch
block, and ST segment abnormalities
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unstable angina that required hospitalization, coronary
revascularization procedures (surgery or angioplasty),
and sudden death.
Stress echocardiography protocol
An accelerated high-dose dipyridamole protocol was
used for all patients. Dipyridamole was infused intra-
venously at a dose of 0.84 mg/kg body weight over
6 min. Aminophylline was routinely administered to
patients with negative findings 10 min after the initi-
ation of the test. Two-dimensional echocardiography
and 12-lead electrocardiography (EKG) were used for
continuous monitoring during the test and the recovery
phase. Blood pressure measurements using a cuff were
recorded every minute. Echocardiographic images were
semiquantitatively assessed using a 17 segments,
4-point scale model of the left ventricle. Wall motion
score index (WMSI) was derived by dividing the sum of
individual segment scores by the number of interpret-
able segments. Ischemia was defined as stress-induced
new and/or worsening of pre-existing wall motion ab-
normality, or biphasic response (i.e. low-dose improve-
ment followed by high-dose deterioration). Inotropic
reserve was defined as any improvement of WMSI dur-
ing stress in the absence of inducible ischemia. Necrotic
pattern was akinetic or diskinetic myocardium with no
thickening during stress. An hypokinetic segment that
did not worsen during ischemic challenge was consid-
ered a rest wall motion abnormality (WMA). A test was
normal in case of no rest and stress WMA. A test was
considered positive for ischemia when at least 2 adja-
cent segments of the same vascular territory showed an
increment of WMSI (worsening or regional function) of
at least 1 point at peak stress [18]. The following cri-
teria were used for a premature interruption of the test:
onset of obvious new wall motion abnormalities, severe
chest pain, horizontal or downsloping ST-depression ≥
2 mm, ST-segment elevation ≥ 1.5 mm, symptomatic
hypotension and/or bradycardia, supra-ventricular or ven-
tricular tachyarrythmias, and intolerable symptoms. Intra-
venous aminophylline (up to 240 mg) was immediately
available to reverse the effects of dipyridamole. As recom-
mended by Dal Porto et al. [19], each patient’s intravenous
cannula remained in situ for 1 h after the stress test in the
event of a late event occurring after the procedure. All the
tests were performed by the same echocardiographer, who
had more than 15 years of experience.
Statistical analyses
Quantitative variables were expressed as mean, median,
and standard deviation, and qualitative variables as fre-
quencies and percentages. Positive and negative predict-
ive values and accuracy were calculated according to
standard formulas. Kaplan-Meier survival estimations
were performed for age, hypertension, smoking, CAD,
and results of stress testing. The log-rank test was used
to compare survival curves. An adjusted Cox regression
model was used for multivariate analysis of variables,
considering stress echo result and the presence of CAD
as explanatory variables, with p-values <0.05. P-values
<0.05 indicated statistical significance. Data were ana-
lyzed using the software program SPSS v. 20.0.
Results
Stress echocardiography result
Two-hundred fifty patients had presented negative di-
pyridamole stress echocardiography results. Of the 14
patients (5 %, n = 264) with positive stress echocardiog-
raphy, 7 had undergone the procedure as a routine clin-
ical and imaging follow-up, 5 for chest pain, 1 for an
inconclusive exercise EKG test, and 1 for heart failure.
Of the 70 patients who had undergone an exercise EKG
test before pharmacological stress echocardiography,
only 1 presented positive dipyridamole stress test and 3
patients developed a cardiovascular event during the
follow-up period.
Follow-up data
We were unable to establish contact with 219 patients.
We attribute that to changes in telephone network rules.
Follow-up data were available for 264 patients (163
women; mean age 64.3 ± 10.5 years, mean duration of
follow-up 32.7 ± 15 months, median duration 30 months,
minimum 6 months). There were 18 cardiovascular events
including cardiovascular deaths during the follow-up
period. Cardiovascular deaths included the following: 1
sudden death 24 months after a negative stress test, 1 after
surgical myocardial revascularization 2 months after a
negative stress test, 1 due to acute myocardial infarction
12 months after a negative stress test, and 1 due to acute
myocardial infarction 24 months after a positive stress
test. There were 14 other cardiovascular events (nonfatal
myocardial infarction, unstable angina that required
hospitalization, and coronary revascularization proce-
dures) in 14 patients during follow-up: 9 after a negative
Table 2 Indications for pharmacologic stress echo
Indications 483 -N(%) 264 - N(%)
Routine clinical and imaging follow-up 123 (25 %) 72 (27 %)
Thoracic pain 107 (22 %) 58 (22 %)
Perioperative risk stratification 76 (15 %) 41 (15 %)
Evaluation of known coronary artery
disease
69 (14 %) 37 (14 %)
Altered resting EKG 30 (6 %) 19 (7 %)
Dyspnea/fatigue 18 (4 %) 12 (4 %)
Altered/insufficient exercise stress testing
(N/%)
132 (27 %) 70 (26 %)
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stress echo test and 5 after a positive stress echo test. The
positive predictive value of stress echocardiography was
42 % and the negative predictive value was 96 %. The ac-
curacy was 92 %. We did not calculate the sensitivity and
specificity of the test in this study, because most patients
did not undergo coronary angiography, even after a posi-
tive stress test. The referring physician made the decision
whether or not to perform coronary angiography. Of 250
patients with a negative stress test, there were 12 (4.8 %)
in whom a cardiovascular event occurred during a mean
follow-up period of 20 ± 16 months. Most events occurred
at least 1 year after the test. In those 14 patients (5 %, n =
264) with positive stress echocardiography there were 6
events (42 %, n = 14) during a mean follow-up of 13 ±
13 months. In those patients with known CAD there were
10 % of cardiovascular events during the follow-up period
compared to 5 % of cardiovascular events in the patients
without CAD. Univariate analysis for all cardiovascular
events showed that there was no significant difference for
gender, age (cut-off, 65 years), hypertension, dyslipid-
emia, or smoking. A Cox regression model showed
that CAD (hazard ratio [HR] 5.4, 95 % confidence
interval [CI] 1.9-15.4; p = 0.002) and positive stress
echocardiography (HR 7.1, 95 % CI 2.5-20.5; p < 0.001)
were significant predictors of cardiovascular events
(Table 3; Figs. 1, 2, and 3).
Discussion
The utility of stress testing modalities for asymptomatic
diabetic patients remains an area of active interest and
study. Diabetic patients have significantly higher rates of
silent ischemia than the general population, and that
could in part explain the more advanced CAD seen on
initial presentation and the worse outcomes in these pa-
tients [20]. The absence of myocardial ischemia on non-
invasive tests of patients with DM does not necessarily
identify a lower-risk cohort. In the present study most of
patients (250) had a negative stress echo and presented
4.8 % of cardiovascular event during the follow-up
period. This may be related, at least in part, to the obser-
vation that diffuse coronary dysfunction in diabetic pa-
tients precedes overt atherosclerosis and regional wall
motion abnormalities of the left ventricle are harder to
identify by stress echocardiography, because the reduced
perfusion is global instead of regional [1, 8–13]. Thus,
the current guidelines recommend that all diabetic pa-
tients should be treated as if they have CAD with regard
to blood pressure management, lipid-level goals, and
other secondary preventive measures. Clinicians should
make efforts to stratify the long-term risk of CAD-
associated morbidity and mortality in diabetic patients
in order to identify those patients who need more ag-
gressive treatment strategies. The guidelines of the
Table 3 Risk of cardiovascular events according to Cox
regression model for multivariate analysis






Coronary artery disease <0.001 0.002 5.4 (1.9-15.4)
Positive stress echo <0.001 <0.001 7.1 (2.5-20.5)
*Log-rank test, p < 0.05
**Cox Regression Model and Wald test, p < 0.05
HR hazard rate
Fig. 1 Cumulative proportion survival curve for cardiovascular events
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American College of Cardiology/American Heart Asso-
ciation and the American Diabetes Association recom-
mend screening for CAD in diabetic patients with an
abnormal resting EKG indicating myocardial infarction,
with carotid or peripheral arterial disease, symptoms
suggesting CAD, or 2 or more cardiovascular risk factors
irrespective of the presence of CAD symptoms [21–22].
However, as seen in this study, these guidelines do not
seem to satisfy physicians regarding the risk stratification
of diabetic patients. Our results showed that 25 % of pa-
tients underwent pharmacological stress echocardiog-
raphy with the only indication being that they had DM
and stress echo is a safe procedure [23]. The annual rate
of hard events occurring in diabetic patients with a
normal stress echocardiogram ranges from 1.6 % to 6 %,
whereas the corresponding rate in nondiabetic patients
ranges from 0.6 % to 2.7 %. In addition, in patients with
DM the event rate increases sharply in the second year
after the procedure [24]. In our study, 4.8 % of patients
had an event during a mean follow-up period of 18 ±
14 months in patients with a negative stress test, most oc-
curring 1 year after the test. By contrast, among those pa-
tients with a positive stress test, there were about 4-fold
more events during a mean follow-up of 13 ± 13 months.
These findings are similar to other studies [12, 25–26].
Cortigiani et al. [5] compared the prognostic value of
pharmacologic stress echocardiography in chest pain pa-
tients with and without DM, (mean age 60 ± 10 years) and
Fig. 2 Cumulative proportion survival curve for the presence of coronary artery disease
Fig. 3 Cumulative proportion survival curve for positive stress echocardiography
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positive exercise electrocardiography. During a median
follow-up of 26 months, the results of stress echocardiog-
raphy added prognostic value to the positive exercise elec-
trocardiography results. Both diabetic and nondiabetic
patients with nonischemic stress echocardiography results
had lower annual rates of major events compared with the
overall population of diabetic and nondiabetic patients
with positive electrocardiography results. However, in our
study, most patients did not undergo exercise stress testing
before pharmacological stress echocardiography. Patients
referred for pharmacological stress echocardiography have
been found to have a higher risk for cardiovascular events
than those referred for exercise testing, which likely re-
flects more severe underlying cardiovascular disease and
comorbidities [12]. When our patients were asked why
they did not undergo an EKG exercise stress test before
the pharmacological stress test, most answered that their
private physician asked directly for a pharmacological test
regardless of whether they could undergo an exercise test.
Of the 70 patients who underwent exercise EKG testing
before pharmacological echocardiography only 1 had a
positive dipyridamole stress test and we found only three
cardiovascular events during the follow-up period in these
patients. It appears that physicians simply do not believe
that an exercise test is adequate for stratifying their dia-
betic patients. In our study, the time to occurrence of car-
diovascular events was significant shorter in patients with
a positive echocardiography stress test compared to pa-
tients with a negative stress test (13.7 ± 13.2 versus 20.7 ±
16.6 months, respectively). However, most cardiovascular
events, regardless of the results of stress testing, occurred
around 18 months after the procedure, which suggests that
patients with DM should undergo another imaging stress
test 12 months after their first test. In a study assessing
long-term outcomes of patients with diabetes (N = 230)
and limited exercise capability, dobutamine stress echocar-
diography provided prognostic value for about 7 years
after the initial test [27]. However, in both that study and
our study, the lack of data on the duration of diabetes is
an important shortcoming. In addition, the socioeconomic
background of the 2 study cohorts may be different, and
that factor can affect the prognosis and evaluation of the
disease.
Study limitations
The main limitations of this study include: (1) loss of >
50 % of patients in the follow-up period; (2) lack of in-
formation about each patients’ diabetes time course or
renal function; (3) unknown exact number of subjects
under anti-ischemic medical therapy; and (4) lack of data
on patients’ blood pressure control and medication.
These limitations could significantly influence our ana-
lysis and discussion and may have impacted the results
of this study [28–34].
Conclusions
A negative dipyridamole echocardiography test in dia-
betic patients predicts favorable outcome for the first
year of follow-up. A new stress imaging test should be
done after 12 months in diabetic patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LAVB and RPF: participated in the study design, wrote, oriented the
manuscript, and interviewed the patients. RB: participated in the study
design and data collection. MEBV: participated in data collection. NJV:
participated in data collection. JV: participated in data collection. All authors
read and approved the final manuscript.
Author details
1Center of Health and Biological Sciences, Pontificia Universidade Católica do
Paraná, Rua Imaculada Conceição, 1155, Prado Velho, CEP: 80215-901
Curitiba, Paraná, Brazil. 2Department of Internal Medicine, Medical School,
Universidade Federal do Paraná, Rua XV de Novembro, 1299, Centro, CEP:
80060-000 Curitiba, Paraná, Brazil. 3Medical School, Faculdade Evangélica, Rua
Padre Anchieta, 2770, CEP: 80730-000 Curitiba, Paraná, Brazil. 4Pontificia
Universidade Católica do Paraná.
Received: 12 May 2015 Accepted: 21 July 2015
References
1. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association
between coronary vascular dysfunction and cardiac mortality in patients with
and without diabetes mellitus. Circulation. 2012;126:1858–68.
2. Oliveira JLM, Barreto-Filho JAS, Oliveira CRP, Santana TA, Anjos-Andrade FD,
Alves EO, et al. Prognostic value of exercise echocardiography in diabetic
patients. Cardiovascular Ultrasound. 2009;7:24.
3. Hung MJ, Wang CH, Cherng WJ. Can dobutamine stress echocardiography
predict cardiac events in nonrevascularized diabetic patients following acute
myocardial infarction? CHEST. 1999;116:1224–32.
4. Young LH, Wacker FJT, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac
outcomes after screening for asymptomatic coronary artery disease in patients
with type 2 diabetes. The DIAD study: a randomized controlled trial. JAMA.
2009;301:1547–55.
5. Cortigiani L, Bigi R, Sicari R, Landi P, Bovenzi F, Picano E. Prognostic value of
pharmacological stress echocardiography in diabetic and nondiabetic patients
with known or suspected coronary artery disease. JACC. 2006;47:605–10.
6. Kamalesh M, Matorin R, Sawada S. Prognostic value of a negative stress
echocardiographic study in diabetic patients. Am Heart J. 2002;143:163–8.
7. Cortigiani L, Borelli L, Raciti M, Bovenzi F, Picano E, Molinaro S, et al. Prediction
of mortality by stress echocardiography in 2835 diabetic and 11305
nondiabetic patients. Circ Cardiovasc Imaging. 2015;8(5):002757.
8. Chaowalit N, Arruda AL, McCully RB, Bailey KR, Pellikka P. Dobutamine stress
echocardiography in patients with diabetes mellitus. J Am Coll Cardiol.
2006;47:1029–36.
9. Galderizi M, Raia R. Reduction of coronary flow reserve in a patient with type 2
diabetes mellitus without epicardial coronary stenosis. Heart Metab.
2009;45:30–3.
10. Camici PG, Crea F. Medical progress: Coronary microvascular dysfunction.
NEJM. 2007;356:830–40.
11. Pitkãnen OP, Nuutila P, Raitakari OT, Rönnemaa T, Koskinen PJ, Iida H,
et al. Coronary flow reserve is reduced in young men with IDDM.
Diabetes. 1998;47:248–54.
12. Albers AR, Krichavsky MZ, Balady GJ. Stress testing in patients with
diabetes mellitus, Diagnostic and prognostic value. Circulation.
2006;113:583–92.
13. Cognet T, Vervueren PL, Dercle L, Bastié D, Richaud R, Berry M, et al. New
concept of myocardial longitudinal strain reserve assessed by a dipyridamole
infusion using 2D-strain echocardiography: the impact of diabetes and age,
and the prognostic value. Cardiovasc Diabetol. 2013;12:84.
14. Mohty D, Pibarot P, Echahidi N, Poirier P, Dagenais GR, Dumesnil JG.
Reduced systemic arterial compliance measured by routine Doppler
Baroncini et al. Cardiovascular Ultrasound  (2015) 13:35 Page 6 of 7
echocardiography: A new and independent predictor of mortality in
patients with type 2 diabetes mellitus. Atherosclerosis. 2012;225:353–8.
15. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013
ESH/ESC Guidelines for the management of arterial hypertension. The task
force for the management of arterial hypertension of the European Society
of Hypertension (ESH) and of the European Society of Cardiology.
J Hypertens. 2013;31:1281–357.
16. Jonas MA, Oates JA, Ockene JK, Hennekens CH. Statement on smoking and
cardiovascular disease for health care professionals. Circulation.
1992;86:1664–9.
17. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al.
2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults. A report of the American
College of Cardiology/American Heart Association task force on practice
guidelines. Circulation. 2014;129(suppl2):S1–S45.
18. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P,
Poldermans D, et al. Stress echocardiography expert consensus statement
from European Association of Echocardiography. Eur J Echocardiogr.
2008;9:415–37.
19. Dal Porto R, Faletra F, Picano E, Pirelli S, Moreo A, Varga A. Safety, feasibility,
and diagnostic accuracy of accelerated high-dose dipyridamole stress
echocardiography. Am J Cardiol. 2001;87:520–4.
20. Albers AR, Krichavsky MZ, Balady GH. Contemporary reviews in
Cardiovascular Medicine. Stress testing in patients with diabetes mellitus.
Diagnostic and prognostic value. Ciculation. 2006;113:583–92.
21. Anand DV, Lim E, Lahiri A, Bax JJ. The role of non-invasive imaging in the
risk stratification of asymptomatic diabetic subjects. Eur Hear J.
2006;27:905–12.
22. Chopra S, Peter S. Screening for coronary artery disease in patients with
type 2 diabetes mellitus: An evidence-based review. Indian J Endocr Metab.
2012;16:94–101.
23. Elhendy A, van Domburg RT, Poldermans D, Bax JJ, Nierop PR, Geleijnse ML,
et al. Safety and feasibility of dobutamine-atropine stress echocardiography
for the diagnosis of coronary artery disease in diabetic patients unable to
perform an exercise stress test. Diabetes Care. 1998;21:1797–802.
24. Bigi R, Desideri A, Cortigiani L, Baxx JJ, Celegon L, Fiorentini C. Stress
echocardiography for risk stratification of diabetic patients with known or
suspected coronary artery disease. Diabetes Care. 2001;24:1596–601.
25. D’Andrea A, Severino S, Caso P, De Simone L, Liccardo B, Forni A, et al.
Prognostic value of pharmacological stress echocardiography in diabetic
patients. Eur J Echocardiography. 2003;4:202–8.
26. van der Sijde JN, Boiten HJ, Sozzi FB, Elhendy A, van Domburg RT, Schinkel
AFL. Long-term prognostic value of dobutamine stress echocardiography in
diabetic patients with limited exercise capability, A 13-year follow-up study.
Diabetes Care. 2012;35:634–9.
27. UK Prospective. Diabetes Study Group. Tight blood pressure control and risk
of macrovascular and microvascular complications in type 2 diabetes:
UKPDS 38. BMJ. 1999;318:29.
28. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in
patients with hypertension: principal results of the Hypertension Optimal
Treatment (HOT) randomised trial. Lancet. 1998;351:1755–62.
29. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al.
HOT Study Group, Benefits and risks of more intensive blood pressure
lowering in hypertensive patients of the HOT study with different risk
profiles: does a J-shaped curve exist in smokers? J Hypertens.
2003;21:797–804.
30. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A,
et al. Hypertension in people with type 2 diabetes. Can Fam Physician.
2011;57:997–1002.
31. The ACCORD Study Group. Effects of intensive blood-pressure control in
Type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.
32. Schemthaner G, Drexel H, Rosenkranz AR, Schemthaner GH, Watschinger B.
Austrian Diabetes Association. Antihypertensive therapy in diabetes
mellitus – 2012 guidelines of the Austrian Diabetes Association.
Wien Klin Wochenschr. 2012;124 suppl 2:23–7.
33. Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, Berne C,
Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and
cardiovascular diseases developed in collaboration with the EASD: the
Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the
European Society of Cardiology (ESC) and developed in collaboration with
the European Association for the Study of Diabetes (EASD). Eur Heart J.
2013;34:3035–3087
34. Stults B, Jones RE. Management of hypertension in diabetes. Diabetes
Spectrum. 2006;19:25–31.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Baroncini et al. Cardiovascular Ultrasound  (2015) 13:35 Page 7 of 7
